組織型纖溶酶原激活因子(tPA)多克隆抗體
Polyclonal Antibody to Tissue Plasminogen Activator (tPA)
PLAT; T-PA; t-plasminogen activator; Alteplase; Reteplase
- 編號(hào)PAA525Hu01
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 來源多抗制備
- 宿主兔
- 效價(jià)-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 RPA525Hu01-組織型纖溶酶原激活因子(tPA)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液(pH7.4,containing 0.05% Proclin-300,50% glycerol)
- 性狀液體
- 濃度500μg/mL
- 且適物種Mus musculus (Mouse,小鼠), Rattus norvegicus (Rat,大鼠)
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù),請(qǐng)參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 504 ¥ 1176 ¥ 1680 ¥ 4200 ¥ 16800
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
該抗體是針對(duì)tPA的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別tPA。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA525Hu04 | 組織型纖溶酶原激活因子(tPA)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA525Hu05 | 組織型纖溶酶原激活因子(tPA)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA525Hu06 | 組織型纖溶酶原激活因子(tPA)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA525Hu02 | 組織型纖溶酶原激活因子(tPA)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
EPA525Hu62 | 組織型纖溶酶原激活因子(tPA)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA525Hu01 | 組織型纖溶酶原激活因子(tPA)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA525Hu03 | 組織型纖溶酶原激活因子(tPA)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA525Hu61 | 組織型纖溶酶原激活因子(tPA)活性蛋白 | Cell?culture;?Activity?Assays. |
APA525Hu62 | 組織型纖溶酶原激活因子(tPA)活性蛋白 | Cell?culture;?Activity?Assays. |
EPA525Hu61 | 組織型纖溶酶原激活因子(tPA)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA525Hu01 | 組織型纖溶酶原激活因子(tPA)多克隆抗體 | WB; IHC; ICC; IP. |
PAA525Hu02 | 組織型纖溶酶原激活因子(tPA)多克隆抗體 | WB; IHC; ICC; IP. |
MAA525Hu22 | 組織型纖溶酶原激活因子(tPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA525Hu24 | 組織型纖溶酶原激活因子(tPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA525Hu26 | 組織型纖溶酶原激活因子(tPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA525Hu23 | 組織型纖溶酶原激活因子(tPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA525Hu21 | 組織型纖溶酶原激活因子(tPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA525Hu28 | 組織型纖溶酶原激活因子(tPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA525Hu25 | 組織型纖溶酶原激活因子(tPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA525Hu27 | 組織型纖溶酶原激活因子(tPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA525Hu29 | 組織型纖溶酶原激活因子(tPA)單克隆抗體 | WB; IHC; ICC; IP. |
SEA525Hu | 組織型纖溶酶原激活因子(tPA)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA525Hu | 組織型纖溶酶原激活因子(tPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Annals of Clinical & Laboratory Science | Alteration of Hemostatic Parameters in Patients with Different Levels of Subclinical Hypothyroidism and the Effect of L-thyroxine Treatment [pubmed:28249913] |
Cellular Physiology and Biochemistry | Defective Platelet Activation and Bleeding Complications upon Cholestasis in Mice [pubmed:28441661] |
Journal of allergy and clinical immunology | Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema. [pubmed:27826093] |
European Journal of Neuroscience | Urokinase receptor and tissue plasminogen activator as immediate‐early genes in pentylenetetrazole‐induced seizures in the mouse brain [Pubmed: 31587391] |
Phytomedicine | Sodium aescinate significantly suppress postoperative peritoneal adhesion by inhibiting the RhoA/ROCK signaling pathway [Pubmed: 32120245] |
Sci Rep | Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis [Pubmed:35013379] |